Literature DB >> 1510265

Osmolalities of propylene glycol-containing drug formulations for parenteral use. Should propylene glycol be used as a solvent?

A Doenicke1, A E Nebauer, R Hoernecke, M Mayer, M F Roizen.   

Abstract

Propylene glycol (PG) is a widely used vehicle for water-insoluble drugs. Injection of drugs formulated with this solvent often results in pain, thrombosis, or thrombophlebitis that can be reduced by premedication with local anesthetics or opioids. Because osmolality and pH that are unphysiologic may cause these adverse effects, we assessed the contribution of PG to the osmolality of parenteral drug formulations. Osmolality of PG measured in distilled water showed that PG content and osmolality were directly related: 2% wt/vol PG, 264 mOsm/L; 100% PG, 15, 200 mOsm/L. The osmolalities of commercially available preparations of drugs dissolved in PG ranged from 365 mOsm/L (2% PG content) to 12,800 mOsm/L (83.46% PG), with most above 1000 mOsm/L. Replacement of PG by a solvent with lower osmolality in Germany has effectively reduced the incidence of side effects for one drug. Until PG can be replaced in drugs, we recommend diluting drugs in a large volume of saline solution; this may help to minimize the undesirable effects of this solvent.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1510265     DOI: 10.1213/00000539-199209000-00020

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  2 in total

1.  Through the cleared aorta: three-dimensional characterization of mechanical behaviors of rat thoracic aorta under intraluminal pressurization using optical clearing method.

Authors:  Eijiro Maeda; Yoriko Ando; Kazuhiro Takeshita; Takeo Matsumoto
Journal:  Sci Rep       Date:  2022-05-23       Impact factor: 4.996

2.  Etomidate and propylene glycol activate nociceptive TRP ion channels.

Authors:  Florian Niedermirtl; Mirjam Eberhardt; Barbara Namer; Andreas Leffler; Carla Nau; Peter W Reeh; Katrin Kistner
Journal:  Mol Pain       Date:  2018-10-22       Impact factor: 3.395

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.